Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2008

Poniard Exercises Option to License Kinase Inhibitors from Scripps

  • Poniard Pharmaceuticals finalized an agreement with The Scripps Research Institute to license protein kinase inhibitors resulting from their almost three-year collaboration. In August 2005, Poniard (then NeoRx) forged a collaboration with Scripps focused on discovering small molecule, multitargeted, protein kinase inhibitors as therapeutic agents, including cancer treatments.

    Poniard gave Scripps $2.5 million over 26 months to support the research and retained an option to negotiate a worldwide, exclusive license to any compounds developed through the collaboration.

    "We are pleased with the productive collaboration with Scripps and we are continuing to build on the progress of this collaboration to identify compounds that have significant potential to treat cancer and other diseases," says Jerry McMahon, Ph.D., chairman and CEO of Poniard.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »